Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) was the target of a large increase in short interest in the month of December. As of December 29th, there was short interest totalling 9,749,519 shares, an increase of 9.6% from the December 15th total of 8,894,839 shares. Currently, 14.2% of the shares of the company are sold short. Based on an average trading volume of 2,362,490 shares, the short-interest ratio is presently 4.1 days.

Ampio Pharmaceuticals (NYSEAMERICAN AMPE) traded down $0.03 during trading on Wednesday, hitting $2.94. 1,007,600 shares of the stock were exchanged, compared to its average volume of 3,279,283. Ampio Pharmaceuticals has a fifty-two week low of $0.38 and a fifty-two week high of $4.95. The stock has a market capitalization of $190.19, a price-to-earnings ratio of -14.70 and a beta of 0.51.

Separately, ValuEngine raised shares of Ampio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 11th.

TRADEMARK VIOLATION NOTICE: “Short Interest in Ampio Pharmaceuticals Inc (AMPE) Increases By 9.6%” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/10/short-interest-in-ampio-pharmaceuticals-inc-ampe-increases-by-9-6.html.

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.